FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896917872> ?p ?o ?g. }

• W2896917872 endingPage "viii539" @default.
• W2896917872 startingPage "viii538" @default.
• W2896917872 abstract "Background: BRAF mutations are found in 2-3% of NSCLC. BRAF inhibitors reportedly have antitumor activity. The French National Cancer Institute (INCa) launched a program giving nationwide access to vemurafenib for cancer pts with BRAF-mutated tumors and supporting molecular screening. We report here the results of the NSCLC cohort. Methods: BRAF mutational status was assessed on INCa molecular genetic centers by direct sequencing or NGS. Pts with BRAF V600E mutation, progressing after ≥1 standard treatment were proposed vemurafenib 960 mg BID. Objective Response Rate (ORR) was assessed using RECIST v1.1 every 8 weeks. A sequential Bayesian approach was planned to allow early stopping using an inefficacy boundary for ORR of 10%. If no early stopping occurred, the treatment was considered worthy for further evaluation if there was a 90% probability that the estimated ORR is ≥ 30%, the efficacy boundary. Results: From 10/2014 to 10/2017, 101 NSCLC pts harboring BRAF V600E were enrolled. Median age: 68 years (range 41–85), 68% smokers, 50% females, 100% non-squamous histology and 19% with ECOG PS 2. Most frequent grade ≥3 adverse events (AEs) were asthenia (10% of pts), epidermoid carcinoma (7%), dermatitis (6%) and increased GGT (6%). Three toxic deaths were reported: 1 nausea and vomiting leading to dehydration, 1 pneumonia and 1 neutropenic sepsis. Among the enrolled pts, 100 BRAF V600E NSCLC pts evaluable for the best overall response (BOR), 43 PR, 21 SD, 16 PD, 12 deaths before assessment and 8 not evaluable (no tumor assessment) were observed. The mean objective response rate was 44.9% (95% CI: 35.2; 54.8), the efficacy boundary was reached with a predictive probability greater than 90%. Median duration of response was 6.5 months (5.1-7.3). Median progression-free survival (PFS) was 5.2 months (3.8-6.9) and median OS was 9.3 months. Nine pts were still on treatment at the cut-off date, 91 have stopped vemurafenib (55 PD, 23 AEs, 3 deaths, 1 doctor’s decision, 9 patient’s decisions). Conclusions: Vemurafenib provided reasonable response rate and prolonged PFS in BRAF V600E pretreated NSCLC. These results confirm the activity of BRAF inhibitors in these pts and underline the need of integrating BRAF V600E in biomarkers routine screening. Clinical trial identification: NCT02304809. Legal entity responsible for the study: UNICANCER. Funding: ARC Foundation French National Cancer Institute (INCa) Roche. Disclosure: J. Mazières: Ad Board, Research grant: Roche, BMS, Astra Zeneca. F. Barlesi: Honoraria: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Clovis Oncology, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer and Takeda. V. Avrillon: Advisory Board: Roche, BMS. G. Ferretti: Speaker conference: Boehringer, Roche, GEMS. J.Y. Blay: Advisory Board: Roche, Lilly, Ignyta, Deciphera, Novartis, Bayer, BMS; Corporate-sponsored Research: Roche, Lilly, Ignyta, Deciphera, Novartis, Bayer, Novartis, GSK, AstraZeneca, MSD; Other Substantive Relationships: Surveillance committee of Innate Pharma. All other authors have declared no conflicts of interest." @default.
• W2896917872 created "2018-10-26" @default.
• W2896917872 creator A5000029967 @default.
• W2896917872 creator A5012166159 @default.
• W2896917872 creator A5015396175 @default.
• W2896917872 creator A5022875313 @default.
• W2896917872 creator A5023080520 @default.
• W2896917872 creator A5025297415 @default.
• W2896917872 creator A5027488058 @default.
• W2896917872 creator A5035680745 @default.
• W2896917872 creator A5040336299 @default.
• W2896917872 creator A5044218617 @default.
• W2896917872 creator A5048112844 @default.
• W2896917872 creator A5051063803 @default.
• W2896917872 creator A5051730942 @default.
• W2896917872 creator A5055246540 @default.
• W2896917872 creator A5059099902 @default.
• W2896917872 creator A5065886715 @default.
• W2896917872 creator A5068051498 @default.
• W2896917872 creator A5070551146 @default.
• W2896917872 creator A5087836238 @default.
• W2896917872 creator A5090234903 @default.
• W2896917872 date "2018-10-01" @default.
• W2896917872 modified "2023-09-26" @default.
• W2896917872 title "Vemurafenib in patients (pts) harboring BRAF V600 mutation: Results of non-small cell lung cancer (NSCLC) cohort from the AcSé trial" @default.
• W2896917872 doi "https://doi.org/10.1093/annonc/mdy292.109" @default.
• W2896917872 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32137400" @default.
• W2896917872 hasPublicationYear "2018" @default.
• W2896917872 type Work @default.
• W2896917872 sameAs 2896917872 @default.
• W2896917872 citedByCount "0" @default.
• W2896917872 crossrefType "journal-article" @default.
• W2896917872 hasAuthorship W2896917872A5000029967 @default.
• W2896917872 hasAuthorship W2896917872A5012166159 @default.
• W2896917872 hasAuthorship W2896917872A5015396175 @default.
• W2896917872 hasAuthorship W2896917872A5022875313 @default.
• W2896917872 hasAuthorship W2896917872A5023080520 @default.
• W2896917872 hasAuthorship W2896917872A5025297415 @default.
• W2896917872 hasAuthorship W2896917872A5027488058 @default.
• W2896917872 hasAuthorship W2896917872A5035680745 @default.
• W2896917872 hasAuthorship W2896917872A5040336299 @default.
• W2896917872 hasAuthorship W2896917872A5044218617 @default.
• W2896917872 hasAuthorship W2896917872A5048112844 @default.
• W2896917872 hasAuthorship W2896917872A5051063803 @default.
• W2896917872 hasAuthorship W2896917872A5051730942 @default.
• W2896917872 hasAuthorship W2896917872A5055246540 @default.
• W2896917872 hasAuthorship W2896917872A5059099902 @default.
• W2896917872 hasAuthorship W2896917872A5065886715 @default.
• W2896917872 hasAuthorship W2896917872A5068051498 @default.
• W2896917872 hasAuthorship W2896917872A5070551146 @default.
• W2896917872 hasAuthorship W2896917872A5087836238 @default.
• W2896917872 hasAuthorship W2896917872A5090234903 @default.
• W2896917872 hasBestOaLocation W28969178721 @default.
• W2896917872 hasConcept C104317684 @default.
• W2896917872 hasConcept C121608353 @default.
• W2896917872 hasConcept C126322002 @default.
• W2896917872 hasConcept C143998085 @default.
• W2896917872 hasConcept C185592680 @default.
• W2896917872 hasConcept C197934379 @default.
• W2896917872 hasConcept C2776131300 @default.
• W2896917872 hasConcept C2776256026 @default.
• W2896917872 hasConcept C2776470698 @default.
• W2896917872 hasConcept C2778570526 @default.
• W2896917872 hasConcept C2779984678 @default.
• W2896917872 hasConcept C2780580376 @default.
• W2896917872 hasConcept C2994587330 @default.
• W2896917872 hasConcept C31760486 @default.
• W2896917872 hasConcept C501734568 @default.
• W2896917872 hasConcept C535046627 @default.
• W2896917872 hasConcept C55493867 @default.
• W2896917872 hasConcept C71924100 @default.
• W2896917872 hasConcept C72563966 @default.
• W2896917872 hasConceptScore W2896917872C104317684 @default.
• W2896917872 hasConceptScore W2896917872C121608353 @default.
• W2896917872 hasConceptScore W2896917872C126322002 @default.
• W2896917872 hasConceptScore W2896917872C143998085 @default.
• W2896917872 hasConceptScore W2896917872C185592680 @default.
• W2896917872 hasConceptScore W2896917872C197934379 @default.
• W2896917872 hasConceptScore W2896917872C2776131300 @default.
• W2896917872 hasConceptScore W2896917872C2776256026 @default.
• W2896917872 hasConceptScore W2896917872C2776470698 @default.
• W2896917872 hasConceptScore W2896917872C2778570526 @default.
• W2896917872 hasConceptScore W2896917872C2779984678 @default.
• W2896917872 hasConceptScore W2896917872C2780580376 @default.
• W2896917872 hasConceptScore W2896917872C2994587330 @default.
• W2896917872 hasConceptScore W2896917872C31760486 @default.
• W2896917872 hasConceptScore W2896917872C501734568 @default.
• W2896917872 hasConceptScore W2896917872C535046627 @default.
• W2896917872 hasConceptScore W2896917872C55493867 @default.
• W2896917872 hasConceptScore W2896917872C71924100 @default.
• W2896917872 hasConceptScore W2896917872C72563966 @default.
• W2896917872 hasLocation W28969178721 @default.
• W2896917872 hasOpenAccess W2896917872 @default.
• W2896917872 hasPrimaryLocation W28969178721 @default.
• W2896917872 hasRelatedWork W1585348844 @default.
• W2896917872 hasRelatedWork W1979036864 @default.
• W2896917872 hasRelatedWork W2039455780 @default.
• W2896917872 hasRelatedWork W2347967707 @default.

• next